Exosome Diagnostics Inc., a leader in the liquid biopsy market, today (July 24, 2017) announced the close of its $30 million Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners. Blue Ridge Capital, NGN Capital, Arcus Ventures, b-to-v Partners, CD Ventures, and others participated in the round, which was oversubscribed. Exosome Diagnostics intends to use the funds to support the rapid commercial expansion of its ExoDx® Prostate(IntelliScore) and other diagnostic tests in the oncology market. The company will also continue to leverage its proprietary technologies for tests in other areas, such as neurodegenerative diseases, transplant rejection monitoring, and cardiology. Exosome Diagnostics will continue to invest in the expansion of its companion diagnostics (CDx) business and build out its exosomal instrumentation business by expanding its placement of units in the CDx market and continuing its point-of-care clinical development roadmap. These divisions and technology differentiators, such as one reaction RNA and cell-free DNA interrogation within its pipeline for signal enhancement, and its “Shahky” point-of-care instrumentation which is based on, sample in - answer out, protein biomarker interrogation capabilities, will further distinguish Exosome Diagnostics as the industry leader in the liquid biopsy space, the company believes. The preservation of Exosomes in the isolation process is essential, and will be vital for the derivation of highly specific and sensitive diagnostic tests.
Login Or Register To Read Full Story